RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood samples from patients with refractory non-small cell lung cancer previously treated with sorafenib tosylate.
OBJECTIVES: * To determine the mutation rates of BRAF, KRAS, and EGFR in patients with non-small cell lung cancer treated with sorafenib tosylate on protocol ECOG-2501. * To determine the association between BRAF, KRAS, or EGFR mutation status and clinical benefits in patients treated with this regimen. OUTLINE: This is a multicenter study. DNA is isolated from archived plasma samples and analyzed for BRAF, KRAS, and EGFR mutations.
Study Type
OBSERVATIONAL
Enrollment
80
Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR
Time frame: 1 mont
Association between BRAF, KRAS, and EGFR mutation status and clinical benefits (stable disease or partial response)
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.